2022 - Research.com Best Female Scientist Award
Susan M. Chang focuses on Glioma, Internal medicine, Surgery, Oncology and Pathology. Her study in Glioma is interdisciplinary in nature, drawing from both Brain tumor, Central nervous system disease and Extent of resection. Her Central nervous system disease research incorporates elements of Biopsy and Nuclear medicine.
Her Surgery research includes elements of Clinical trial and Hazard ratio. Her Oncology study combines topics in areas such as Epidermal growth factor receptor, Survival rate, Radiation therapy, Temozolomide and Rash. Her studies in Pathology integrate themes in fields like Tumor progression and Blood volume.
Her scientific interests lie mostly in Glioma, Internal medicine, Oncology, Radiation therapy and Surgery. The concepts of her Glioma study are interwoven with issues in Brain tumor, Pathology and Magnetic resonance imaging. Her research in Magnetic resonance imaging intersects with topics in Tumor progression, Nuclear medicine and Medical imaging.
Her studies in Temozolomide, Clinical trial, Phases of clinical research, Chemotherapy and Progression-free survival are all subfields of Internal medicine research. Her studies deal with areas such as Medical physics, Neurologic Oncology and Intensive care medicine as well as Clinical trial. Her Oncology study deals with Glioblastoma intersecting with Newly diagnosed.
The scientist’s investigation covers issues in Glioma, Internal medicine, Cancer research, Clinical trial and Brain tumor. Her study in the field of Temozolomide is also linked to topics like Patient-reported outcome. Her Internal medicine research includes themes of Anticonvulsant and Oncology.
Her research integrates issues of Glioblastoma and Chemotherapy in her study of Oncology. In Clinical trial, Susan M. Chang works on issues like Intensive care medicine, which are connected to Response assessment and Disease. While the research belongs to areas of Brain tumor, Susan M. Chang spends her time largely on the problem of Cancer, intersecting her research to questions surrounding Neurologic Oncology.
Her main research concerns Glioma, Brain tumor, Intensive care medicine, Clinical trial and Cancer research. Her Temozolomide study in the realm of Glioma interacts with subjects such as World health. Her Brain tumor research incorporates themes from Cancer, Internal medicine, Oncology and Magnetic resonance imaging, Radiology.
In the field of Internal medicine, her study on Interquartile range and Tumor progression overlaps with subjects such as Window of opportunity. The various areas that Susan M. Chang examines in her Oncology study include Retrospective cohort study, Molecular pathogenesis and Glioblastoma. Susan M. Chang has included themes like Drug action and Pharmacodynamics in her Clinical trial study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen;David R. Macdonald;David A. Reardon;Timothy F. Cloughesy.
Journal of Clinical Oncology (2010)
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors
Jeanette E Eckel-Passow;Daniel H Lachance;Annette M. Molinaro;Kyle M. Walsh.
The New England Journal of Medicine (2015)
Role of Extent of Resection in the Long-Term Outcome of Low-Grade Hemispheric Gliomas
Justin S. Smith;Edward F. Chang;Kathleen R. Lamborn;Susan M. Chang.
Journal of Clinical Oncology (2008)
Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma
Brett E. Johnson;Tali Mazor;Chibo Hong;Michael Barnes.
Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project.
Edward R. Laws Jr.;Ian F. Parney;Wei Huang;Frederick A. Anderson Jr..
Journal of Neurosurgery (2003)
Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis
Kathleen R. Lamborn;Susan M. Chang;Michael D. Prados.
Response assessment criteria for brain metastases: proposal from the RANO group
Nancy U Lin;Eudocia Q Lee;Hidefumi Aoyama;Igor J Barani.
Lancet Oncology (2015)
Variants in the CDKN2B and RTEL1 regions are associated with high grade glioma susceptibility
Margaret Wrensch;Robert B. Jenkins;Jeffrey S. Chang;Ru Fang Yeh.
Nature Genetics (2009)
Radiosurgery for brain metastases: is whole brain radiotherapy necessary?
Penny K Sneed;Kathleen R Lamborn;Julie M Forstner;Michael W McDermott.
International Journal of Radiation Oncology Biology Physics (1999)
Seizure characteristics and control following resection in 332 patients with low-grade gliomas
Edward F. Chang;Matthew B. Potts;G. Evren Keles;Kathleen R. Lamborn.
Journal of Neurosurgery (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: